Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib

Background: The contribution of Autophagy to Cancer therapy resistance remains complex, mainly owing to the discrepancy of Autophagy mechanisms in different therapy. However, the potential mechanisms of autophagy-mediated resistance to icotinib have yet to be elucidated.

Methods: The effect of Autophagy in icotinib resistance was examined using a series of in vitro and in vivo assays. The results above were further verified in biopsy specimens of lung Cancer patients before and after icotinib or gefitinib treatment.

Results: Icotinib increased ATG3, ATG5, and ATG7 expression, but without affecting Beclin-1, Vps34 and ATBG14 levels in icotinib-resistant lung Cancer cells. Autophagy blockade by 3-MA or silencing Beclin-1 had no effects on resistance to icotinib. CQ effectively restored lung Cancer cell sensitivity to icotinib in vitro and in vivo. Notably, aberrantly activated STAT3 and highly expressed FOXM1 were required for Autophagy induced by icotinib, without the involvement of AMPK/mTOR pathway in this process. Alterations of STAT3 activity using genetic and/or pharmacological methods effectively affected FOXM1 and ATG7 levels increased by icotinib, with altering Autophagy and icotinib-mediated Apoptosis in resistant cells. Furthermore, silencing FOXM1 impaired up-regulated ATG7 induced by STAT3-CA and icotinib. STAT3/FOXM1 signalling blockade also reversed resistance to icotinib in vivo. Finally, we found a negative correlation between STAT3/FOXM1/ATG7 signalling activity and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) treatment efficacy in patients undergoing EGFR-TKIs treatment.

Conclusions: Our findings support that STAT3/FOXM1/ATG7 signalling-induced Autophagy is a novel mechanism of resistance to icotinib, and provide insights into potential clinical values of ATG7-dependent Autophagy in icotinib treatment.